Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro

References

• Barone JA. (1999). Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother 33:429–40
   PubMed Web of Science ®Google Scholar
• Boyce MJ, Baisley KJ, Warrington SJ. (2011). Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 73:411–21
   Web of Science ®Google Scholar
• Bozigian H, Pritchard J, Gooding A, Pakes G. (1994). Ondansetron absorption in adults: effect of dosage form, food, and antacids. J Pharm Sci 83:1011–13
   PubMed Web of Science ®Google Scholar
• Brown H, Galetin A, Hallifax D, Houston J. (2006). Prediction of in vivo drug–drug interactions from in vitro data: factors affecting prototypic drug–drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035–50
   PubMed Web of Science ®Google Scholar
• Brown H, Ito K, Galetin A, Houston J. (2005). Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508–18
   PubMed Web of Science ®Google Scholar
• Budde K, Neumayer H, Fritsche L, et al. (2003). The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368–74
   PubMed Web of Science ®Google Scholar
• Chang SY, Fancher RM, Zhang H, Gan J. (2010). Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica 40:138–45
   PubMed Web of Science ®Google Scholar
• Choi J, Burm J. (2008). Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. Arch Pharm Res 31:1200–4
   PubMed Web of Science ®Google Scholar
• Chu V, Einolf HJ, Evers R, et al. (2009). In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective. Drug Metab Dispos 37:1339–54
   PubMed Web of Science ®Google Scholar
• Cornish-Bowden A. (1974). A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137:143–4
   PubMed Web of Science ®Google Scholar
• Dixon C, Colthup P, Serabjit-Singh C, et al. (1995). Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225–30
   PubMed Web of Science ®Google Scholar
• Drolet B, Rousseau G, Daleau P, et al. (2000). Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102:1883–5
   PubMed Web of Science ®Google Scholar
• Fischer V, Vickers A, Heitz F, et al. (1994). The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 22:269–74
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2012). Draft guidance for industry. Drug interaction studies – study design, data analysis, and implications for dosing and labelling recommendations. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf [last accessed 24 August 2012]
   Google Scholar
• Friedenberg F, Parkman H. (2006). Delayed gastric emptying: whom to test, how to test, and what to do. Curr Treat Options Gastroenterol 9:295–304
   PubMedGoogle Scholar
• Gibaldi M, Perrier D. (1982). Pharmacokinetics. Dekker
   Google Scholar
• Glazer N. (2000). Pioglitazone does not induce cytochrome P450 isoform CYP3A4 [Rapid Responses]. Available from: http://www.bmj.com/rapid-response/2011/10/28/pioglitazone-does-not-induce-cytochrome-p450-isoform-cyp3a4 [last accessed 10 March 2014]
   Google Scholar
• Goodman LS, Hardman JG, Limbird LE, Gilman AG. (2001). Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill
   Google Scholar
• Hanefeld M. (2001). Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 121:19–25
   Google Scholar
• Horowitz M, Harding PE, Maddox AF, et al. (1989). Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32:151–9
   PubMed Web of Science ®Google Scholar
• Ito K, Hallifax D, Obach R, Houston J. (2005). Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug–drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837–44
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Backman J, Neuvonen M, et al. (2006). Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 61:70–8
   PubMed Web of Science ®Google Scholar
• Jann M, ZumBrunnen T, Tenjarla S, et al. (1998). Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy 18:288–94
   PubMed Web of Science ®Google Scholar
• Jolliet P, Nion S, Allain-Veyrac G, et al. (2007). Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood–brain barrier. Pharmacol Res 56:11–17
   PubMed Web of Science ®Google Scholar
• Kajosaari L, Jaakkola T, Neuvonen P, Backman J. (2006). Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 62:217–23
   PubMed Web of Science ®Google Scholar
• Korzekwa KR, Nagar S, Tucker J, et al. (2012). Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab Dispos 40:865–76
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Bailey CJ, Melander A. (2000). Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ 321:252–3
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. (1998). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200–5
   PubMed Web of Science ®Google Scholar
• Lim H, Duczak NJ, Brougham L, et al. (2005). Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 33:1211–19
   PubMed Web of Science ®Google Scholar
• Lyrenås EB, Olsson EH, Arvidsson UC, et al. (1997). Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes. Relationship to postprandial blood glucose concentrations. Diabetes Care 20:413–18
   PubMed Web of Science ®Google Scholar
• Margolis JM, Obach RS. (2003). Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606–11
   PubMed Web of Science ®Google Scholar
• Masaoka T, Tack J. (2009). Gastroparesis: current concepts and management. Gut Liver 3:166–73
   PubMed Web of Science ®Google Scholar
• Meuldermans W, Hurkmans R, Swysen E, et al. (1981). On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 6:49–60
   PubMedGoogle Scholar
• Michaud V, Turgeon J. (2010). Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes. Drug Metab Lett 4:69–76
   PubMedGoogle Scholar
• Naoumova RP, Kindler H, Leccisotti L, et al. (2007). Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 50:2051–8
   PubMed Web of Science ®Google Scholar
• Obach RS. (1996). The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro–in vivo correlations. Drug Metab Dispos 24:1047–9
   PubMed Web of Science ®Google Scholar
• Obach RS. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359–69
   PubMed Web of Science ®Google Scholar
• Obach R, Walsky R, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 35:246–55
   PubMed Web of Science ®Google Scholar
• Orr ST, Ripp SL, Ballard TE, et al. (2012). Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure–activity relationships and discovery strategies to mitigate drug–drug interaction risks. J Med Chem 55:4896–933
   PubMed Web of Science ®Google Scholar
• Polasek T, Elliot D, Lewis B, Miners J. (2004). Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996–1007
   PubMed Web of Science ®Google Scholar
• Reddymasu S, Soykan I, McCallum R. (2007). Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 102:2036–45
   PubMed Web of Science ®Google Scholar
• Sahi J, Black C, Hamilton G, et al. (2003). Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439–46
   PubMed Web of Science ®Google Scholar
• Schinkel AH. (1999). P-glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev 36:179–94
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Mol CA, van Deemter L. (1996). P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517–24
   PubMed Web of Science ®Google Scholar
• Segel I. (1993). Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems. Wiley
   Google Scholar
• Simard C, Michaud V, Gibbs B, et al. (2004). Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 34:1013–23
   PubMed Web of Science ®Google Scholar
• Tran TH, Von Moltke LL, Venkatakrishnan K, et al. (2002). Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30:1441–5
   PubMed Web of Science ®Google Scholar
• Ung D, Parkman H, Nagar S. (2009). Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. Xenobiotica 39:749–56
   PubMed Web of Science ®Google Scholar
• Villikka K, Kivistö K, Neuvonen P. (1999). The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 65:377–81
   PubMed Web of Science ®Google Scholar
• Ward B, Morocho A, Kandil A, et al. (2004). Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58:277–87
   PubMed Web of Science ®Google Scholar
• Weiss J, Sauer A, Herzog M, et al. (2009). Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology 84:264–70
   PubMed Web of Science ®Google Scholar
• Wittayalertpanya S, Chompootaweep S, Thaworn N. (2006). The pharmacokinetics of pioglitazone in Thai healthy subjects. J Med Assoc Thai 89:2116–22
   PubMedGoogle Scholar
• Wong H, Ozalp Y, Lainesse A, Alpan R. (2004). In vivo bioequivalence of oral antidiabetic agents: pioglitazone tablets. Arzneimittelforschung 54:618–24
   PubMed Web of Science ®Google Scholar
• Wu M, Gao L, Cai X, Wang G. (2002). Determination of domperidone in human plasma by LC–MS and its pharmacokinetics in healthy Chinese volunteers. Acta Pharmacol Sin 23:285–8
   PubMed Web of Science ®Google Scholar
• Youssef AS, Argikar UA, Pathikonda M, et al. (2013). Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC–ESI–MS/MS. Xenobiotica 43:1073–83
   Google Scholar
• Zhang L, Zhang YD, Zhao P, Huang SM. (2009). Predicting drug–drug interactions: an FDA perspective. The AAPS J 11:300–6
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, et al. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304
   PubMed Web of Science ®Google Scholar